Abstract: A genetically modified mesenchymal stem cell including an exogenous nucleic acid including a Klotho encoding region operably linked to a promoter or promoter/enhancer combination, wherein the genetically modified mesenchymal stem cell exhibits increased Klotho expression compared to an unmodified mesenchymal stem cell. Also disclosed are methods of treating a patient including administering a therapeutically effective number of the genetically modified mesenchymal stem cells to the patient. The methods of treatment include treating the patient for a neurodegenerative disease; cancer; organ fibrosis; renal disease; age-related changes of organs or organ systems; to slow, reverse and/or inhibit aging; arteriosclerosis; dementia; diabetes mellitus; erectile dysfunction; autoimmune diseases or autoimmune-related diseases; an inflammatory disease of the lung and sepsis.

Abstract: A method for treating a subject having a medical condition associated with inflammation and/or an unwanted immune response without an alpha1-antitrypsin (AAT) deficiency, wherein the method comprises administering genetically modified mesenchymal stem cells to the subject, wherein said genetically modified mesenchymal stem cells comprise an exogenous nucleic acid comprising (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.

Abstract: Mesenchymal stem cells (MSCs) for use in the treatment of a tumor, wherein said treatment comprises the combined administration of said mesenchymal stem cells with an anti-tumor immunotherapy, and wherein said MSCs do not comprise exogenous nucleic acids that encode immune response-stimulating cytokines. In a preferred embodiment the invention relates to the use of said MSCs in the treatment of a tumor and/or malignant disease, wherein the anti-tumor immunotherapy for combined administration comprises the administration of a cellular immunotherapy, preferably chimeric antigen receptor (CAR) T cells, wherein said T cell receptor binds specifically to a tumor-associated antigen, and the mesenchymal stem cells are not genetically modified.

Abstract: A method of treating a tumor in a subject including administering a genetically modified mesenchymal stem cell (MSC), wherein the MSC includes one or more exogenous nucleic acid molecule(s), wherein the one or more exogenous nucleic acid molecule(s) includes one or more regions encoding two or more immune response-stimulating cytokines operably linked to one or more promoters or promoter/enhancer combinations, wherein the two or more immune response-stimulating cytokines include at least IL-7, and at least one of IL-12 or IL-21.

Abstract: A genetically modified mesenchymal stem cell including an exogenous nucleic acid including a Klotho encoding region operably linked to a promoter or promoter/enhancer combination, wherein the genetically modified mesenchymal stem cell exhibits increased Klotho expression compared to an unmodified mesenchymal stem cell. Also disclosed are methods of treating a patient including administering a therapeutically effective number of the genetically modified mesenchymal stem cells to the patient. The methods of treatment include treating the patient for a neurodegenerative disease; cancer; organ fibrosis; renal disease; age-related changes of organs or organ systems; to slow, reverse and/or inhibit aging; arteriosclerosis; dementia; diabetes mellitus; erectile dysfunction; autoimmune diseases or autoimmune-related diseases; an inflammatory disease of the lung and sepsis.

Abstract: A motor vehicle has a body; an air-guide, fastenable to the body; a drive to adjust the air-guide when the air-guide is fastened to the body; and connectors that connect the drive to the body. The connectors include first fastening elements and second fastening elements. The first fastening elements are insertable through cutouts in the body into the second fastening elements via a first position up to a second position. An orientation of the drive relative to the body is possible in the first position, and the second fastening elements exert a clamping force on the first fastening elements in the second position.

Abstract: A method for treating a subject having a medical conditions associated with inflammation and/or an unwanted immune response, and said subject does not have an alpha1-antitrypsin (AAT) deficiency, wherein the method includes administering genetically modified mesenchymal stem cells to the subject, wherein said genetically modified mesenchymal stem cells include an exogenous nucleic acid including (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.

Abstract: A method of treating a tumor in a subject including administering a genetically modified mesenchymal stem cell (MSC), wherein the MSC includes one or more exogenous nucleic acid molecule(s), wherein the one or more exogenous nucleic acid molecule(s) includes one or more regions encoding two or more immune response-stimulating cytokines operably linked to one or more promoters or promoter/enhancer combinations, wherein the two or more immune response-stimulating cytokines include at least IL-7, and at least one of IL-12 or IL-21.

Abstract: A motor vehicle has a body; an air-guide, fastenable to the body; a drive to adjust the air-guide when the air-guide is fastened to the body; and connectors that connect the drive to the body. The connectors include first fastening elements and second fastening elements. The first fastening elements are insertable through cutouts in the body into the second fastening elements via a first position up to a second position. An orientation of the drive relative to the body is possible in the first position, and the second fastening elements exert a clamping force on the first fastening elements in the second position.

Abstract: A spoiler system for a vehicle includes a spoiler body having a spoiler surface for influencing an air flow around the vehicle; and a spoiler receptacle having a sealing device with a seal configured to provide sealing between the sealing device and a sealing surface of the spoiler body during an extension movement of the spoiler body from a retracted position into an extended position. The spoiler body is movably mounted on the spoiler receptacle between the retracted position in which the spoiler body is received at least partially in the spoiler receptacle and the extended position in which the spoiler body is extended at least partially out of the spoiler receptacle.

Abstract: A spoiler arrangement of a motor vehicle includes a spoiler blade, a body portion to which the spoiler blade attaches, a displacement device for the spoiler blade, the displacement device being configured to move the spoiler blade relative to the body portion between a retracted position and an extended position; and a cover configured to attach to the spoiler blade and to at least partially close a rear gap which is formed, in the extended position of the spoiler blade, between a rear edge of the spoiler blade and an adjoining assembly of the body portion.

Abstract: A tumor or a malignant disease can be treated by the combined administration of mesenchymal stem cells (MSCs) with an anti-tumor immunotherapy. The MSCs need not be genetically modified, and do not include exogenous nucleic acids that encode immune response-stimulating cytokines. The anti-tumor immunotherapy can be a cellular immunotherapy, such as administration of chimeric antigen receptor (CAR) T cells, in which the T cell receptor binds specifically to a tumor-associated antigen.

Abstract: A spoiler arrangement of a motor vehicle includes a spoiler blade, a body portion to which the spoiler blade attaches, a displacement device for the spoiler blade, the displacement device being configured to move the spoiler blade relative to the body portion between a retracted position and an extended position; and a cover configured to attach to the spoiler blade and to at least partially close a rear gap which is formed, in the extended position of the spoiler blade, between a rear edge of the spoiler blade and an adjoining assembly of the body portion.

Abstract: A spoiler system for a vehicle includes a spoiler body having a spoiler surface for influencing an air flow around the vehicle; and a spoiler receptacle having a sealing device with a seal configured to provide sealing between the sealing device and a sealing surface of the spoiler body during an extension movement of the spoiler body from a retracted position into an extended position. The spoiler body is movably mounted on the spoiler receptacle between the retracted position in which the spoiler body is received at least partially in the spoiler receptacle and the extended position in which the spoiler body is extended at least partially out of the spoiler receptacle.

Abstract: A genetically modified mesenchymal stem cell (MSC) includes an exogenous nucleic acid that includes a Klotho encoding region operably linked to a promoter or promoter/enhancer combination. The MSCs can be used for the treatment of cancer, organ fibrosis, renal failure, age-related changes of organs or organ systems, arteriosclerosis, and neurodegenerative diseases, such as Alzheimer's disease (AD), Multiple sclerosis (MS), Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease, and Schizophrenia, as well as dementia, diabetes mellitus, sepsis and autoimmune diseases and autoimmune-related diseases.

Abstract: Genetically modified mesenchymal stem cells can be used as a medicament in the treatment of medical conditions associated with inflammation and/or an unwanted immune response in subjects without an alpha1-antitrypsin (AAT) deficiency. The stem cells include an exogenous nucleic acid, which includes (i) an Alpha-1 antitrypsin (AAT) encoding region operably linked to (ii) a promoter or promoter/enhancer combination.

Abstract: A genetically modified mesenchymal stem cell (MSC) and medical use thereof in the treatment of tumors, the MSC including one or more exogenous nucleic acid molecule(s), wherein the exogenous nucleic acid molecule(s) include a region encoding one or more immune response-stimulating or immune response-modulating cytokine(s) operably linked to a promoter or promoter/enhancer combination. The invention encompasses the use of the cells in modulating the tumor microenvironment in order to attract immune effector cells and facilitate their activation and/or adoption of a memory phenotype.

Abstract: A top for a convertible, which has a rear window frame with a rear window and, in the closed state, at least one roof section situated in front of the rear window frame in the direction of travel. When there are two roof sections which are adjacent to each other when the top is closed, a respective extension, which is extended to the rear or front, is formed on the lateral border regions of one of the roof sections. The extension being configured as a seal carrier.

Abstract: A convertible has a top which can be opened and can be put away and which has a rear window frame and, when the top is closed, at least one surface bow situated in front of said rear window frame in the direction of travel. A coupling linkage for carrying out a relative movement of the surface bow with respect to the rear window frame is arranged between the rear window frame and the surface bow. It is essential for the invention that at least two surface bows which are situated in front of the rear window frame in the direction of travel are provided, which surface bows, when the top is closed, form a continuous roof contour together with the rear window frame. Furthermore, the coupling linkage is designed in such a manner that, at the beginning of the opening of the top, the second surface bow can be moved downward relative to the adjacent first surface bow and relative to the rear window frame out of the roof contour.

Abstract: A vehicle roof has at least two roof segments which, in the closed position of the roof, support a flexible roof skin at least in some regions and can be shifted via at least two pairs of links in a positively controlled manner from a closed position G of the top into a fixed storage position A of the top and vice-versa. One pair of links is thereby drivable by motor in order to move all of the roof parts. In the storage position A of the top, the driven pair of links can be supported by a first vehicle-body-side stop on each side of the vehicle in order to fix all of the roof parts with defined distances being maintained at least between the at least two pairs of links.